Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Immunterapi eller målrettet terapi med eller uten stereootaktisk radiokirurgi for pasienter med hjernemetastaser fra melanom eller ikke-småcellet lungekreft (USZ-STRIKE)

9. november 2026 oppdatert av: ETOP IBCSG Partners Foundation

En multisenter randomisert åpen fase III-studie av stereootaktisk radiokirurgi, i tillegg til standard systemisk terapi for pasienter med metastatisk melanom eller nylig diagnostisert metastatisk NSCLC og asymptomatiske eller oligosymptomatiske hjernemetastaser

The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

180

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Naples, Italia
      • Padova, Italia
      • Perugia, Italia
        • Rekruttering
        • Santa Maria della Misericordia Hospital
        • Ta kontakt med:
      • Roma, Italia
        • Rekruttering
        • Istituto Nazionale Tumori "Regina Elena"
        • Ta kontakt med:
      • Rome, Italia
      • Siena, Italia
      • Amsterdam, Nederland
        • Rekruttering
        • NKI-AVL
        • Ta kontakt med:
      • Barcelona, Spania
        • Rekruttering
        • Vall Hebron Institute of Oncology (VHIO)
        • Ta kontakt med:
      • Majadahonda, Spania
        • Rekruttering
        • Hospital Puerta de Hierro
        • Ta kontakt med:
      • Valencia, Spania
        • Rekruttering
        • Hospital La Fe
        • Ta kontakt med:
      • London, Storbritannia
      • Manchester, Storbritannia
      • Bern, Sveits
      • Winterthur, Sveits
      • Zurich, Sveits
        • Rekruttering
        • Universitätsspital Zürich
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Most important inclusion criteria:

  • Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.

  • Requirements for brain metastases:

  • Brain metastases must be previously untreated, except for surgery.

  • Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.

  • Number and size of metastases at diagnosis of brain metastases:

    • Maximum 1-10 brain metastases at screening
    • At least one brain metastasis must be of ≥5 mm in diameter
    • In case of 1-4 brain metastases:
    • Longest diameter of largest brain metastasis must be ≤30 mm
    • In case of 5-10 brain metastases:
    • Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
    • Maximum cumulative brain metastases volume must be ≤30 mL
  • Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC

  • Requirements for patients with melanoma:

  • Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).

  • BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).

  • Requirements for patients with NSCLC:

  • Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.

  • Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)

  • Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).

  • Age of 18 years or older

  • Karnofsky performance status of 60 or more

  • Life expectancy >12 weeks

  • Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).

  • Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.

  • Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.

Most important exclusion criteria:

  • Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
  • Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
  • Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
  • Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
  • Prior whole brain irradiation or focal radiation therapy to the brain
  • Prior systemic treatment for brain metastases
  • Contra-indication for SRS
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  • Women who are pregnant or in the period of lactation.
  • Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Standard systemic treatment with stereotactic radiosurgery (SRS)

Arm A

Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of >20 mm or for >4 brain metastases.

For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation.

Systemic therapy follows the current standard of care, according to the type of the primary tumour.

  • For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of

    • an approved immune-checkpoint inhibition combination therapy (cohort 1a) or
    • an approved immune-checkpoint inhibition monotherapy (cohort 1b).
  • For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).

  • For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy).

Andre navn:
  • standard behandling
Aktiv komparator: Standard systemic treatment without stereotactic radiosurgery

Arm B

Systemic therapy follows the current standard of care, according to the type of the primary tumour.

  • For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of

    • an approved immune-checkpoint inhibition combination therapy (cohort 1a) or
    • an approved immune-checkpoint inhibition monotherapy (cohort 1b).
  • For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).

  • For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy).

Andre navn:
  • standard behandling

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
CNS-specific PFS, locally assessed as per iRANO criteria
Tidsramme: from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months

The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy.

from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studiestol: Michael Weller, MD, University of Zurich
  • Studiestol: Rolf Stahel, MD, ETOP IBCSG Partners Foundation

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. november 2022

Primær fullføring (Antatt)

1. juni 2027

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

23. august 2022

Først innsendt som oppfylte QC-kriteriene

30. august 2022

Først lagt ut (Faktiske)

31. august 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere